Marco Meglio

The director and founder of The MS Center for Innovations in Care provided perspective on some of the significant strides made in recent years to improve the care and access to affordable treatments for patients with multiple sclerosis.

In a small-scale trial, patients with Parkinson disease on accelerated theta-burst transcranial ultrasound demonstrated higher motor evoked potentials than those on sham, with no statistically significant changes in MDS-UPDRS-III scores.

Stratification of the cohort into low- and elevated-cardiovascular risk groups revealed no differences in cardiovascular adverse events with repetitive DHE; however, elevated-risk patients had higher mean arterial blood pressure.

Following treatment with diazepam, patients achieved resolution of clinical relevant seizures within 10 minutes, with no adverse events that led to discontinuation or respiratory depression.

Diego Torres-Russotto, MD, chair of neurology at Baptist Health Miami Neuroscience Institute, provided an overview of the upcoming 11th Annual Miami Neuroscience Symposium, a 3-day educational event held in early November.

In animal models, HL192 showed disease-modifying effects, as demonstrated through improvements in behavioral deficits.

Among football players, odds of having a parkinsonism or Parkinson disease diagnosis were greater with more seasons and higher level of football play.

PRO-PD showed good 6-month test-retest reliability, as well as good convergent validity between other widely used validated scales of PD.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Mitzi Joi Williams, MD; Rhonda Voskuhl, MD, PhD; Tom Fuchs, MD, PhD; Barry Singer, MD; and Georgina Arrambide, MD, PhD. [LISTEN TIME: 15 minutes]

The 40-week study includes 150 patients with documented patent foramen ovale closure and migraine who are randomized to either the GORE CARDIOFORM Septal Occluder or sham.

After a median follow-up of 19 months, only the physical component on the Multiple Sclerosis Impact Scale was worsened in the discontinuation group.

Findings from the study further confirmed target engagement of BHV-7000, with future plans of a potential phase 3 trial in focal epilepsy later this year.

Over a 6-month treatment period, investigators observed either stabilization or improvement on outcomes of Expanded Disability Status Scale, MFIS, T25FW, and pyramidal score.

The head of Biogen’s MS and Immunology Department Unit provided an overview of FUSION, a currently recruiting study assessing the efficacy and safety of BIIB091 as a monotherapy and in combination with diroximel fumarate.

With the approval, zilucoplan becomes the first once-daily subcutaneous C5 complement inhibitor available for adults with generalized myasthenia gravis.

Over an 11-week treatment period, patients on pitolisant experienced improvements in secondary outcomes of behavioral symptoms, behavioral disturbances, and hyperphagia.

Over a 24-month follow-up, investigators observed increased ganglion cell loss that could potentially be associated with an enhanced risk of developing progression without relapse activity.

Solanezumab did not slow the progression of preclinical Alzheimer disease as compared with placebo on the basis of the primary or secondary cognitive and functional end points over a 4.5-year treatment period.

Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided comment on a recently published randomized controlled trial assessing the therapeutic potential of an augmented reality program for postural instability and gait dysfunction in Parkinson disease.

AOC 1001 consistently demonstrated directional improvements across multiple aspects of myotonic dystrophy type 1, including measures of myotonia, strength, function, and patient reported outcome.

In preclinical data, treatment with PGN-EDODM reduced pathogenic nuclear foci by 54% per nuclei and liberated muscleblind like splicing regulator 1, resulting in a greater than 68% correction of downstream transcript missplicing events.

The decision opens the door for greater access to PET imaging that can assist in timely diagnosis of Alzheimer disease and facilitate with appropriate treatment decisions.

Over a 6-month period, ofatumumab-treated patients met the primary end point of no change or reduction in the number of gadolinium-enhancing lesions on MRI.

Despite not showing significant associations, those with B cell suppression had longer time to relapse, new MRI activity, and progression independent of relapse activity than those without.

Using a minimally invasive neuromodulation device, patients showed decreases in Overactive Bladder questionnaire symptoms and increases in OAB-q quality of life scores.

After Supernus met with the FDA earlier this year, the company believes it has addressed the agency’s requests mentioned in its complete response letter delivered in October 2022.

Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.

The director of the MedStar Georgetown Headache Center gave commentary on the advances in the treatment of migraine, ways to better utilize CGRP medications, and the introduction of PACAP-targeting agents and their relevancy.

In comparison with placebo, treatment with remote ischemic conditioning was not associated with a significant shift toward better functional outcome at 90 days.

Loneliness was associated with a higher risk of subsequent PD after accounting for basic demographic variables and other risk, protective, prodromal, or confounding factors.